Redhill Biopharma Ltd.

(RDHL) Trade

By |

Profile

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Contact Information

Website: www.redhillbio.com
Email: investors@redhillbio.com
Main Phone: +972 35413131
Address: 21 Ha'arba'a Street
City / Town: Tel Aviv
Country: IL
Postal Code: 6473921

Issuer Information

Exchange: NSD
CEO: Dror Ben-Asher
Employees: 155
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Contact Information

Website: www.redhillbio.com
Email: investors@redhillbio.com
Main Phone: +972 35413131
Address: 21 Ha'arba'a Street
City / Town: Tel Aviv
Country: IL
Postal Code: 6473921

Issuer Information

Exchange: NSD
CEO: Dror Ben-Asher
Employees: 155
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 8.79 $ -0.21 (-2.33%)
Last Price 8.79 Change $ -0.21 Change % -2.33 Tick N/A
Bid 8.50 Bid Size 200.00 Ask 9.30 Ask Size 1,000.00
Open 9.34 High 9.37 Low 8.74 Prev Close 9.00
Last Trade Volume 493,129 52 Wk Hi 11.36 52 Wk Low 3.27
Market Cap 328.8 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 37,408,604.00 EPS (TTM) -1.50 PE Ratio -5.30 Exchange NSD
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 36 36 36 36
Low Target Price Estimate 17 17 17 17
Mean Target Price Estimate 24 24 24 24
Standard Deviation 10.44 10.44 10.44 10.44
Date of Most Recent Estimate 05/14/18 05/14/18 05/14/18 05/14/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 4 4 4 4
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 1